OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Chagpar on the SHAVE Trial for Breast Cancer

July 1st 2015

Anees B. Chagpar, MD, discusses initial results of the SHAVE trial for patients with breast cancer.

Dr. Diefenbach on Ipilimumab/Brentuximab Vedotin in Patients With RR Hodgkin Lymphoma

June 30th 2015

Catherine M. Diefenbach, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses a phase I study with an expansion cohort examining the combination of ipilimumab and brentuximab vedotin for the treatment of patients with relapsed/refractory Hodgkin lymphoma.

Dr. Saad on Radium-223 in Patients with mCRPC

June 29th 2015

Fred Saad, MD, FRCS, professor, Department of Surgery, University of Montreal, discusses the use of radium-223 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Guarino on IMMU-132 in Advanced Metastatic Lung Cancer

June 26th 2015

Michael J. Guarino, MD, senior staff member, Christiana Care's Department of Medicine, partner, Medical Oncology Hematology Consultants, Christiana Care's Helen F. Graham Cancer Center, discusses initial data from a phase I/ll study examining an anti-Î¤ROP-2-SN-38 antibody-drug conjugate, sacituzumab govitecan (IMMU-132), as therapy for advanced metastatic lung cancer.

Dr. James Lee on Overcoming Mismatched Repair in Colorectal Cancer

June 25th 2015

James J. Lee, MD, PhD, Assistant Professor of Medicine, Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, discusses mismatched repair in colorectal cancer.

Dr. Voss on Bevacizumab With CRLX101 in Advanced RCC

June 25th 2015

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses a phase II study examining bevacizumab combined with CRLX101 in patients with advanced renal cell carcinoma.

Dr. Leonard on Lenalidomide With Rituximab in Follicular Lymphoma

June 24th 2015

John P. Leonard, MD, medical oncology, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, discusses an ongoing study examining the use of lenalidomide combined with rituximab in patients with recurrent follicular lymphoma.

Dr. Ernstoff Discusses Nivolumab and Ipilimumab in Advanced Melanoma

June 23rd 2015

Marc Ernstoff, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses results from a study examining the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with advanced BRAF-mutated or BRAF wild-type melanoma.

Dr. Chanan-Khan Discusses Ibrutinib and BR in CLL

June 23rd 2015

Asher A. Chanan-Khan, MD, chair, Hematology/Oncology, Cancer Center, Mayo Clinic, discusses ibrutinib (Imbruvica) combined with rituximab and bendamustine (BR) as treatment of chronic lymphocytic leukemia (CLL) from a mechanism of action point of view.

Dr. Hershman on Late Effects of Intermittent ADT for Prostate Cancer Patients

June 23rd 2015

Dawn Hershman, MD, Associate Professor Medicine at Columbia University Medical Center, discusses the late-effects of intermittent androgen deprivation therapy (ADT) to continuous ADT in prostate cancer.

Dr. Esteva Discusses T-DM1 in HER2-Positive Breast Cancer

June 22nd 2015

Francisco J. Esteva, MD, PhD, professor, Department of Medicine, associate director, Clinical Investigation Perlmutter Cancer Center, director, Breast Medical Oncology Program, NYU Langone Medical Center, discusses the efficacy of T-DM1 in patients with HER2-positive breast cancer.

Dr. Gary Schwartz on the Survival Benefit of Eribulin In Sarcoma

June 19th 2015

Gary Schwartz, MD, a medical oncologist and chief of the Hematology and Oncology Division at Columbia University Medical Center, discusses a randomized phase III trial investigating eribulin (Halaven) versus dacarbazine in patients with leiomyosarcoma and adipocytic sarcomas.

Nagi Kumar on Green Tea Catechin Treatment for Prostate Cancer Prevention

June 18th 2015

Nagi B. Kumar, PhD, Professor/Director, Cancer Chemoprevention, Moffitt Cancer Center, discusses the potential of green tea catechins for the prevention of prostate cancer.

Dr. O'Regan Discusses Breast Cancer Index in HER2-Positive/HR-Positive Patients

June 17th 2015

Ruth O'Regan, MD, medical oncology, Breast Cancer Clinic, University of Wisconsin Carbone Cancer Center, faculty, University of Wisconsin School of Medicine and Public Health, evaluates the Breast Cancer Index in patients with HER2-positive, HR-positive breast cancer for risk of late recurrence and endocrine benefit.

Dr. Rafii Discusses Clinical Outcomes With Olaparib in Patients with Ovarian Cancer

June 16th 2015

Saeed Rafii, MD, PhD, MRCP, medical director, Sarah Cannon Research Institute, discusses factors that influence clinical outcomes to olaparib in patients with BRCA1/2-mutant ovarian cancer.

Dr. Khorana on Blood Clots in Patients with Cancer

June 15th 2015

Alok Khorana, MD, medical oncologist, Cleveland Clinic, discusses blood clot risk and treatment for patients with cancer.

Melinda Irwin on Impact of Exercise on Survivors' Quality of Life

June 15th 2015

Melinda Liggett Irwin, PhD, MPH, associate professor of epidemiology (chronic diseases), Yale School of Public Health, co-program leader, Cancer Prevention and Control Research Program, Yale Cancer Center, discusses the impact of the LIVESTRONG at the YMCA Program on survivors' fitness, physical activity, and quality of life.

Holli Dilks on Molecular Profiling

June 12th 2015

Holli Dilks, PhD, Director, Personalized Medicine Operations Sarah Cannon Research Institute, discusses molecular profiling.

Dr. Goldberg on PD-1 Blockade in Tumors with Mismatch Repair Deficiency

June 12th 2015

Richard Goldberg, MD, Ohio State University Comprehensive Cancer Center-James Cancer Hospital, discusses PD-1 blockade in tumors with mismatch repair deficiency.

Dr. Brahmer on Impact of CheckMate-057 in NSCLC

June 11th 2015

Julie R. Brahmer, MD, interim director, Sidney Kimmel Comprehensive Cancer Center, associate professor of oncology, Johns Hopkins Medicine, discusses how the CheckMate-057 trial could impact the treatment of non-small cell lung cancer (NSCLC).